Text Size

Glucose-dependent Insulinotropic Polypeptide (GIP) and Lipid Metabolism

This study has been completed.
Sponsor:
Information provided by:
Hvidovre University Hospital
ClinicalTrials.gov Identifier:
NCT00999271
First received: October 20, 2009
Last updated: NA
Last verified: October 2009
History: No changes posted
  Purpose

The aim of this proposal is to examine whether endogenous GIP and exogenous GIP alone and in combination with insulin affect gastric emptying (GE), appetite, energy intake, energy expenditure (EE) and plasma levels of triglycerides (TAG), free fatty acids FFA) and glycerol in man.


Condition Intervention
Healthy Subjects
 Other: Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)

Study Type: Observational
Study Design: Observational Model: Case Control
Official Title: On the Role of Glucose-dependent Insulinotropic Polypeptide, GIP, in Postprandial Metabolism in Humans

Resource links provided by NLM:

Drug Information available for: Dextrose
U.S. FDA Resources

Further study details as provided by Hvidovre University Hospital:

Estimated Enrollment: 30
Study Start Date: August 2008
Study Completion Date: September 2009
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Healthy subjects
30 healthy subjects without family history of diabetes or gastrointestinal disease, a normal oral glucose tolerance test (OGTT) and no intake of medicine
 Other: Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)

two different dosages:

  • 0.8 pmol/kg/min
  • 1.5 pmol/kg/min for 300 minutes

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Healthy volunteers

Criteria

Inclusion Criteria:

  • Informed oral and written consent
  • Caucasians over the age of 18 years
  • Normal 75 g oral glucose tolerance test (OGTT)
  • Normal blood haemoglobin concentration
  • Normal plasma lipid profile

Exclusion Criteria:

  • First-degree relatives with diabetes and familial hypertriglyceridemia
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00999271

Locations
Denmark
Hvidovre Hospital
Hvidovre, Denmark, 2650
Sponsors and Collaborators
Hvidovre University Hospital
  More Information

No publications provided

Responsible Party: University of Copenhagen
ClinicalTrials.gov Identifier: NCT00999271     History of Changes
Other Study ID Numbers: HD-2009-0025
Study First Received: October 20, 2009
Last Updated: October 20, 2009
Health Authority: Denmark: The Danish National Committee on Biomedical Research Ethics

Keywords provided by Hvidovre University Hospital:
Glucose-dependent insulinotropic polypeptide
gastric emptying
appetite
energy intake
lipid metabolism

Additional relevant MeSH terms:
Gastric Inhibitory Polypeptide
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
 Physiological Effects of Drugs
Pharmacologic Actions
Gastrointestinal Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 23, 2013